Slide 1: Immunic Therapeutics Third Quarter 2022 Financial Results and Corporate Update
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 216 of the Securities
Slide 3: Agenda
Agenda Third Quarter 2022 Financial Results and Corporate Update Third Quarter 2022 and Subsequent Highlights 04 | Q&A Session 02 | Financial and Operating Results Summary and Highlights Anticipated Clinical Milestones 3. | ©immunic, inc. | Nov/o3/2022 & Immunic
Slide 4: Third Quarter 2022 and Subsequent Highlights
Slide 5: July: Announced Appointment of Maria Tornsén to Board of Directors
July: Announced Appointment of Maria Tornsén to Board of Directors = Industry executive with 20 years of global commercial experience in U.S. and ex-U.S. markets = Jan Van den Bossche resigned from the Board = Both effective July 5, 2022 & Immunic
Slide 6: August: Received Notice of Allowance for Composition-of-Matter Patent for IMU-856
August: Received Notice of Allowance for Composition-of-Matter Patent for IMU-856 Received Notice of Allowance from the U.S. Patent and Trademark Office for patent application 16/646130, entitled, “Compound Having Cyclic Structure” Covers composition-of-matter of IMU-85: related pharmaceutical compo
Slide 7: September: Announced Positive Results from Phase 1 Clinical Trial of IMU-856
September: Announced Positive Results from Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects 7 = Unblinded safety, tolerability and pharmacokinetic results from the single and multiple ascending dose portions of the phase 1 clinical trial of IMU-856 in healthy human subjects = |MU-856 show
Slide 8: October: Closed USD 60 Million Private Placement, Extending Cash Runway Into Q4/2024
October: Closed USD 60 Million Private Placement, Extending Cash Runway Into Q4/2024 = Private investment in public equity (“PIPE”) financing = Aggregate of 8,696,552 shares of common stock at a price of $4.35 per share, and pre- Summary funded warrants to purchase up to an aggregate of 5,096,552 sh
Slide 9: October: Reported Group-Level Interim Data of Phase 1b Trial of IMU-935 in Psoriasis
October: Reported Group-Level Interim Data of Phase 1b Clinical Trial of IMU-935 in Moderate-to-Severe Psoriasis Identifying Therapeutic Activity of IMU-935 in Moderate-to-Severe Psoriasis Patients = 28-day double-blind, placebo-controlled dose escalation trial to evaluate safety, tolerability, phar
Slide 10: Financial and Operating Results
Slide 11: Consolidated Statements of Operations
Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Nine Months Ended: 30, Ended 30, 2022 2021 2022 2021 Operating expenses: Research and development $_ 16,537] $_ 15,48 $50,521 $42,737] General and administrative 3,579 2,907] 11,641] 9,95
Slide 12: Anticipated Clinical Milestones
Slide 13: Vidofludimus Calcium in Multiple Sclerosis
Vidofludimus Calcium in Multiple Sclerosis Straightforward Approval Strategy Phase 3 ENSURE Program in RMSE = Two identical pivotal trials in RMS patients = Goal: Low risk clinical program for regulatory approval of vidofludimus calcium = Dosage: 30 mg vidofludimus calcium QD Phase 2 CALLIPER Trial
Slide 14: IMU-856 Phase 1 Clinical Trial
IMU-856 Phase 1 Clinical Trial Initial data from the ongoing Part C of the phase 1 clinical trial of IMU-856 in celiac disease patients is expected to be available in 2023. & |Immunic
Slide 15: Q&A Session
Slide 16: Summary and Highlights
Slide 17: Advanced Clinical Pipeline
Advanced Clinical Pipeline Three Differentiated Programs in Various Phases of Clinical Development Program _ | Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones = RMS interim analysis planned after approximately half of the events occurred ENSURE-1 trial estimated to readout end of 2025, Vid
Slide 18: Thank You!
Thank You! Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com w.imux.com 18 | ©immunic, inc. | Nov/o3/2022 Immunic, Inc. ; sie 1200 Avenue of the Americas EN sn New York City, NY 10036 ’ : ia ney 82166 Gréfelfing (Munich) Germany Immunic Australia Pty. Ltd .Melbourne Australia §